Compound profile

Selank

The Russian tuftsin-derived peptide studied for calm without sedation

What Selank is, how it is thought to ease anxiety through several pathways at once, typical intranasal dosing and cycling, what the research shows, and its 2026 legal status.

How it works

The mechanism

Not one receptor, but several calming pathways working together.

Modulates GABA

It is described as a positive modulator of GABA-A receptors, the brain's main calming system, the same broad target benzodiazepines act on.

Slows enkephalin breakdown

It inhibits enkephalinase, the enzyme that degrades the body's own calming enkephalin peptides, so their natural effect lasts longer.

Mood and BDNF

Research also points to effects on serotonin turnover and higher BDNF expression, a proposed basis for the mood and mild cognitive effects.

The key difference

Selank vs benzodiazepines

Studied for the same problem, with a very different trade-off on evidence and risk.

Selank

Calm without sedation

Russian clinical work reported anxiolytic effects without the sedation, motor impairment or dependence seen with benzodiazepines. The catch is a small, mostly Russian-language evidence base.

Trade-off: gentler profile, thinner evidence

Benzodiazepines

Proven but with baggage

FDA-approved, with a large independently replicated record. They also carry sedation, tolerance and dependence risk, which is what the Selank comparison is reacting against.

Trade-off: strong evidence, known risks

This is educational context, not a suggestion to replace a prescribed medication.

Evidence

What the research shows

One real clinical study, a clear mechanism, and a thin Western trial base.

Generalized anxiety
ClinicalGAD and neurasthenia

A Russian human trial reported anxiolytic, antiasthenic and mild stimulant effects, without the sedation seen with benzodiazepine comparators.

Zozulya et al., Zh Nevrol Psikhiatr 2008 (PMID 18454096)

Mechanism, human serum
In vitroenkephalinase inhibition

Selank slowed the enzymes that break down enkephalins in human serum, supporting the idea that it prolongs the body's own calming peptides.

Kost et al., Bioorg Khim 2001 (PMID 11443939)

The evidence gap
PreclinicalGABA, serotonin, BDNF

The mechanistic work on GABA, serotonin turnover and BDNF is mostly animal and in-vitro, with little independent Western replication.

Russian-language literature; limited Western trials

The honest breakdown: Selank human research.

Dosing

How it is dosed

Selank is a peptide with poor oral absorption, so it is given intranasally, usually in cycles.

Research-protocol convention
250–900mcg per day

As a nasal spray, one to three times daily. The published GAD study used more, up to about 2,700mcg per day over a 14 to 21 day course.

Cycling convention
2–3 wks on, then off

Commonly two to three weeks on, at least a week off. Borrowed from other GABAergic compounds, not formally tested for Selank.

Educational information, not medical advice; dosing should come from a prescriber. Check your math with the dosage calculator.

Safety

Side effects

Reported as generally well tolerated, with limited long-term data.

  • Nasal irritation: mild discomfort or a runny nose from the intranasal route is the most commonly described effect.
  • No sedation reported: unlike benzodiazepines, the clinical reports did not describe sedation or motor impairment.
  • Dependence: not reported in the Russian studies, but long-term and withdrawal data are thin.
  • Unknown: long-term safety in humans outside the Russian clinical setting is not well characterized.

Caution: most human safety data comes from Russian clinical use. If you take anxiety medication, this is not a substitute, and combining calming compounds is a conversation for a prescriber.

A calm fit woman in her thirties using a nasal spray by a sunlit window at home, relaxed and unhurried
Legal status

Selank's legal status in 2026

Prescription in Russia

Approved in Russia in 2009 as a nasal spray for generalized anxiety disorder. That approval does not carry over to the US.

Research chemical in the US

Not FDA-approved and never FDA-reviewed. Products sold as Selank are for laboratory use only, not for human consumption.

Not in the US compounding policy

Selank was not one of the six peptides in the October 2026 draft HHS policy, so no compounding route exists for it in the US.

More on how to get peptides legally and the FDA peptide status tracker.

Track it

Know if it's working

There is no blood marker for an anxiolytic, so the signal is how you feel, scored consistently over a cycle.

  • Anxiety and mood, scored daily on the same simple scale
  • On and off weeks, to see whether cycling matters for you
  • Sleep and daytime alertness, since the selling point is calm without sedation

The dashboard logs doses and daily ratings, and Rate My Stack scores where it fits a wider stack.

A fit man in his thirties sitting relaxed on a sofa with a mug and a journal, calm morning light, winding down

Frequently asked questions

What is Selank?

Selank is a synthetic heptapeptide developed in Russia at the Institute of Molecular Genetics, built from the immune-signaling tetrapeptide tuftsin with a Pro-Gly-Pro tail added for stability. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is studied mainly as an anxiolytic, a compound that reduces anxiety, with a mild cognitive and mood-supporting profile and without the sedation linked to benzodiazepines.

How does Selank work?

Its calming effect is attributed to several pathways rather than one receptor. The research literature describes positive modulation of GABA-A receptors, inhibition of enkephalinase, the enzyme that breaks down the body's own calming enkephalin peptides, effects on serotonin turnover, and increased BDNF expression. Most of that mechanistic work is animal and in-vitro, so it is best read as a proposed basis rather than settled human pharmacology.

Is Selank FDA-approved or legal?

Selank is not FDA-approved in the United States and has not been reviewed by the FDA for any indication. It is a registered prescription nasal spray in Russia, approved in 2009 for generalized anxiety disorder, but that status does not carry over to the US. It was also not among the six peptides in the October 2026 HHS compounding policy, so in the US it exists only as a research chemical sold for laboratory use, not for human consumption.

What is the typical Selank research dose?

Research-community protocols commonly cite 250 to 900mcg per day, given as an intranasal spray one to three times daily. The published Russian GAD clinical study used higher amounts, up to about 2,700mcg per day over a 14 to 21 day course. This is educational information, not a dosing recommendation; any medical use should come from a prescriber.

Does Selank need to be cycled?

Most research protocols use a cycling approach, commonly two to three weeks on followed by at least a week off, on the reasoning that continuous GABA stimulation could blunt the effect over time. That cycling convention is borrowed from other GABAergic compounds and has not itself been formally tested in controlled Selank trials, so treat it as a common-sense precaution rather than an evidence-based schedule.

How is Selank different from benzodiazepines?

Both are studied for anxiety, but the comparison is what makes Selank interesting: the Russian clinical work reported anxiolytic effects without the sedation, motor impairment or dependence potential associated with benzodiazepines. That said, the benzodiazepine class has a large, independently replicated evidence base and FDA approval, while Selank's comparison rests on a much smaller, mostly Russian-language record.

How is Selank different from Semax?

They are built from different parent molecules and studied for different jobs. Selank comes from tuftsin and is studied for calm and mood. Semax comes from an ACTH fragment and is studied for focus, cognition and neuroprotection. Both are Russian-developed neuropeptides sold in the US as research chemicals, and both influence BDNF, but they are not interchangeable.

Track your protocol

Log doses, anxiety, mood and sleep across each cycle, and see what is actually moving. Free.

Sources

  1. Zozulya AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID 18454096
  2. Kost NV, Sokolov OI, Gabaeva MV, et al. Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorg Khim (Russ J Bioorg Chem). 2001;27(3):180-183. PMID 11443939
  3. Selank: Russian registration as a prescription anxiolytic nasal spray (2009) and development history at the Institute of Molecular Genetics. Wikipedia summary

This content is for informational purposes only and is not medical advice. Selank is not FDA-approved in the United States and was not included in the October 2026 HHS peptide compounding policy. Research-grade Selank is sold for laboratory use only, not for human consumption. If you take medication for anxiety, do not change it based on this page. Always consult a qualified healthcare provider before considering any peptide protocol.